NASH

NASH
Name	Nonalcoholic Steatohepatitis
Synonyms	NASH
Field	Hepatology, Gastroenterology
Symptoms	Often asymptomatic
Complications	Cirrhosis, Hepatocellular carcinoma
Causes	Metabolic syndrome, Insulin resistance
Risks	Obesity, Type 2 diabetes, Dyslipidemia
Diagnosis	Liver biopsy, FibroScan, Blood test
Treatment	Lifestyle modification, Pharmacotherapy, Bariatric surgery
Medication	Pioglitazone, Vitamin E, GLP-1 receptor agonist
Prognosis	Variable; can progress to end-stage liver disease
Frequency	Increasing globally

NASH. Nonalcoholic steatohepatitis is a progressive form of nonalcoholic fatty liver disease characterized by liver cell injury, inflammation, and fat accumulation, which can advance to significant fibrosis. It is closely associated with components of the metabolic syndrome, such as obesity and type 2 diabetes mellitus, and represents a major cause of chronic liver disease worldwide. The condition is often silent in its early stages but poses a substantial risk for the development of cirrhosis and its attendant complications.

Definition and Overview

NASH is defined histologically by the presence of hepatic steatosis, lobular inflammation, and hepatocyte ballooning in individuals who consume little to no alcohol. It exists on a spectrum with nonalcoholic fatty liver, with the key differentiator being the presence of inflammation and injury that drive disease progression. The condition is a leading indicator for liver transplantation in many developed nations, rivaling traditional causes like chronic hepatitis C and alcoholic liver disease. Its recognition has grown substantially since early descriptions by clinicians like Jurgen Ludwig and the team at the Mayo Clinic.

Pathophysiology

The pathogenesis of NASH is complex and multifactorial, centered on the concept of multiple parallel hits. The foundational event is insulin resistance, which promotes increased lipolysis in adipose tissue and de novo lipogenesis in the liver, leading to hepatic steatosis. Subsequent injury is driven by factors including oxidative stress, mitochondrial dysfunction, and release of pro-inflammatory cytokines such as TNF-α from activated Kupffer cells and hepatic stellate cells. Gut-derived endotoxins and alterations in the gut microbiota are also implicated in promoting inflammation and fibrogenesis.

Diagnosis

Diagnosis typically requires exclusion of other liver diseases, such as alcoholic hepatitis, autoimmune hepatitis, and Wilson's disease. While serum biomarkers and imaging tools like FibroScan and magnetic resonance elastography are used for non-invasive assessment, a definitive diagnosis often hinges on percutaneous liver biopsy interpreted using scoring systems like the NAFLD Activity Score. Key laboratory findings may include elevated serum aminotransferases, though alanine aminotransferase levels can be normal. Organizations like the American Association for the Study of Liver Diseases provide detailed practice guidelines.

Management and Treatment

The cornerstone of management is aggressive lifestyle intervention, including weight loss through dietary modification and physical activity, which can reduce steatosis and inflammation. Pharmacologic options are evolving, with pioglitazone and vitamin E recommended in specific patient populations by the European Association for the Study of the Liver. Newer agents targeting metabolic pathways, such as GLP-1 receptor agonists and FXR agonists like obeticholic acid, show promise in clinical trials. For eligible patients with advanced disease, bariatric surgery can be beneficial, and liver transplantation remains the ultimate treatment for decompensated cirrhosis.

Epidemiology

The global prevalence of NASH is rising in tandem with the obesity epidemic and is estimated to affect a significant percentage of the adult population in many countries. It is particularly common among individuals with type 2 diabetes and metabolic syndrome. Major studies, including the Framingham Heart Study and Dallas Heart Study, have helped delineate its burden. The incidence is increasing in regions like the Asia-Pacific, and it is now a common finding in pediatric populations, linked to childhood obesity.

Prognosis and Complications

The natural history of NASH is variable; many have an indolent course, while a subset experiences progressive fibrosis leading to cirrhosis, liver failure, and hepatocellular carcinoma. The risk of progression is higher with the presence of features like type 2 diabetes and more advanced histologic stages. Complications of advanced disease include portal hypertension, variceal hemorrhage, and hepatic encephalopathy. Cardiovascular disease remains a leading cause of mortality in this patient population, underscoring its systemic nature.

Category:Liver diseases Category:Metabolic disorders